Healthcare stocks have outperformed the benchmark indices since the start of the current financial year. The BSE Healthcare Index is up 19 per cent as compared to BSE Sensex returns of 11 per cent during this period.
Nitin Agarwal of DAM Capital highlighted this trend in a report last month. “After a sustained period of underperformance over FY21-23, the BSE Healthcare Index has once again captured the spotlight. The recent uptick in performance has been driven by hospitals and emerging green shoots in pharmaceutical exports, particularly to the US, along with sustaining momentum in domestic branded formulations,” he said.
Within this space, pharma players with major exposure to the US market such as Sun Pharma, Lupin, Zydus Life, Dr Reddy’s,